Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Serretta

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Progress in Clinical and Biological Research|January 1, 1988
The cisplatin-methotrexate neo-adjuvant protocol as first-line therapy of bladder cancer. Present experience in PalermoG B Ingargiola, M Lamartina, G Cassata, et al.
Journal of Endourology|December 22, 1999
Endoprosthesis implantation in the treatment of recurrent urethral stricture: a multicenter study. Sicilian-Calabrian Urology SocietyG Morgia, A Saita, F Morana, et al.
Urologia Internationalis|August 5, 2006
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from Gruppo Studi Tumori Urologici FoundationV Serretta, G Morgia, V Altieri, et al.
British Journal of Cancer|January 8, 2004
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancerW Albrecht, H Van Poppel, S Horenblas, et al.
Aging Clinical and Experimental Research|July 4, 2019
Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomesF Cuccia, A Fiorentino, S Corrao, et al.
Urologia|November 25, 2010
[Results at 48 months of a randomized trial on maintenance after early adjuvant]V Serretta, G Morgia, V Altieri, et al.
Urologia Internationalis|August 30, 2014
The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcomeM Racioppi, L Salmaso, C Brombin, et al.
Actas Urologicas Espanolas|June 20, 2021
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patientsF Pisano, P Gontero, R Sylvester, et al.
World Journal of Urology|September 2, 2018
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomyFrancesco Soria, Francesca Pisano, Paolo Gontero, et al.
World Journal of Urology|May 4, 2018
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thoughtJ Palou, F Pisano, R Sylvester, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Progress in Clinical and Biological Research|January 1, 1988
The cisplatin-methotrexate neo-adjuvant protocol as first-line therapy of bladder cancer. Present experience in PalermoG B Ingargiola, M Lamartina, G Cassata, et al.
Journal of Endourology|December 22, 1999
Endoprosthesis implantation in the treatment of recurrent urethral stricture: a multicenter study. Sicilian-Calabrian Urology SocietyG Morgia, A Saita, F Morana, et al.
Urologia Internationalis|August 5, 2006
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from Gruppo Studi Tumori Urologici FoundationV Serretta, G Morgia, V Altieri, et al.
British Journal of Cancer|January 8, 2004
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancerW Albrecht, H Van Poppel, S Horenblas, et al.
Aging Clinical and Experimental Research|July 4, 2019
Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomesF Cuccia, A Fiorentino, S Corrao, et al.
Urologia|November 25, 2010
[Results at 48 months of a randomized trial on maintenance after early adjuvant]V Serretta, G Morgia, V Altieri, et al.
Urologia Internationalis|August 30, 2014
The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcomeM Racioppi, L Salmaso, C Brombin, et al.
Actas Urologicas Espanolas|June 20, 2021
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patientsF Pisano, P Gontero, R Sylvester, et al.
World Journal of Urology|September 2, 2018
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomyFrancesco Soria, Francesca Pisano, Paolo Gontero, et al.
World Journal of Urology|May 4, 2018
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thoughtJ Palou, F Pisano, R Sylvester, et al.
Pageof 6